Bora Completes Buy of Emergent’s US Sterile Fill/Finish Site

Bora Pharmaceuticals, a Taiwan-headquartered contract development and manufacturing organization (CDMO), has completed the acquisition of Emergent BioSolutions' sterile manufacturing facility in Baltimore-Camden, Maryland, USA. The facility adds drug product fill/finish to Bora’s extensive biologics drug substance capabilities.

The newly acquired 87,000-sq. ft. facility, Bora said, provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral aseptic fill/finish services of vials and pre-filled syringes on four fill lines, lyophilization, formulation development, and support services.

“Following on the heels of our recent acquisition of Upsher-Smith Laboratories, the Camden facility extends our presence in North America, expands our offering for our biologics customers, and advances us further in our goal to become a full service global CDMO,” commented Bobby Sheng, chairman and CEO of Bora. “We look forward to further enhancing the capabilities at the site and welcoming the hugely talented team in Camden to our global family.”

Bora completed the acquisition of Upsher-Smith Laboratories, the Minnesota, US-based generics manufacturer and marketer, in April 2024, adding oral dose capabilities at two facilities in Plymouth and Maple Grove. The Company’s extensive global CDMO network now includes ten high quality manufacturing facilities serving customers across dose forms and delivery technologies.

© Shutterstock / Numstocker
© Shutterstock / Numstocker

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.